Study Summary
This trial is testing a new combination therapy for mantle cell lymphoma, which is a cancer of the lymph nodes. The treatment consists of 12 cycles of three drugs, after which responding patients can enter a maintenance phase. The goal is to see if the treatment is effective and safe.
- Mantle Cell Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: 4 years
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
ALR in Combination
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: Acalabrutinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has Acalabrutinib been given the green light from the Food and Drug Administration?
"Acalabrutinib's safety is assessed as a 2 on our scale because though there are some studies that attest to its security, there are none yet confirming its effectiveness." - Anonymous Online Contributor
What symptoms does Acalabrutinib typically alleviate?
"Acalabrutinib is a commonly used pharmaceutical for treating diffuse large b-cell lymphoma (DLBCL), though it can also be effective in managing other ailments such as patients who have had at least two previous systemic chemotherapy treatments, B-Cell Lymphomas and Polyangium." - Anonymous Online Contributor
How large is the cohort participating in this research project?
"Correct. According to clinicaltrials.gov, this medical study which was originally advertised on October 11th 2019 is still actively recruiting patients. 24 participants must be recruited from a single trial site." - Anonymous Online Contributor
Are there still opportunities for participants in this research trial?
"According to the clinicaltrials.gov data, this research trial is currently open for recruitment with a posting date of October 11th 2019 and an edit on October 17th 2022." - Anonymous Online Contributor